Autologous macrophage therapy - ProNeuron
Alternative Names: Autologous incubated macrophage therapy; ProCordLatest Information Update: 13 Aug 2015
At a glance
- Originator Proneuron Biotechnologies
- Class Cell therapies
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Spinal cord injuries
Most Recent Events
- 13 Aug 2015 No recent reports on development identified - Phase-I for Spinal cord injuries in Belgium (unspecified route)
- 13 Aug 2015 No recent reports on development identified - Phase-II for Spinal cord injuries in Israel, USA (unspecified route)
- 19 Sep 2005 Data from a media release have been added to the adverse events and Neurological Disorders therapeutic trials sections